Joint Order approving the Antimicrobial Resistance Control and Prevention Program and interagency Action Plan 2024-2027.
Country
Type of law
Policy
Abstract
The document outlines the Antimicrobial Resistance (AMR) Control and Prevention Program, emphasizing the need for intersectoral cooperation under the One Health concept. Its primary objectives include the development of policies for AMR regulation, continuous improvement of infection prevention and control systems, and the establishment of a legal framework to ensure appropriate antimicrobial use.
The need for the Program is determined by the following factors: (a) antimicrobial resistance is a phenomenon when microorganisms change over time so much that they no longer respond to antimicrobial medicines; (b) effective antimicrobial medicines, particularly antibacterial medicines, are among the most important elements in increasing human life expectancy; and (c) the discovery of antimicrobial (antibacterial, antifungal, antiviral, antiparasitic) medicines is one of the most important advances in healthcare ever recorded in human history; antimicrobial medicines are an important and valuable resource, but their inappropriate use contributes to the emergence of resistant microorganisms.
The Program operates within the broader context of public health and environmental safety, aiming to mitigate the risks associated with antimicrobial resistance through comprehensive legal and regulatory measures.
The document specifies several key measures and action plans, including the introduction of new tools in outpatient medical records to justify antibacterial therapy, the regulation of systemic antimicrobials for veterinary use, and the analysis of existing legislative frameworks related to environmental emissions. It highlights the importance of developing clinical guidelines, enhancing laboratory capacities, and raising public awareness about AMR.
Compliance requirements include the establishment of oversight mechanisms for prescription practices and the implementation of educational campaigns targeting healthcare professionals and the public.
The implementation plan spans from 2024 to 2027, with specific phases dedicated to ensuring stakeholder involvement and adopting international approaches to AMR prevention. Institutional responsibilities are assigned to various ministries, including Health, Economy, and Environment, which will coordinate efforts to monitor and evaluate the program's progress.
Secondary themes include the need for continuous capacity building among professionals in healthcare, agriculture, and environmental sectors, as well as the involvement of professional medical associations in external monitoring and improvement processes.
The need for the Program is determined by the following factors: (a) antimicrobial resistance is a phenomenon when microorganisms change over time so much that they no longer respond to antimicrobial medicines; (b) effective antimicrobial medicines, particularly antibacterial medicines, are among the most important elements in increasing human life expectancy; and (c) the discovery of antimicrobial (antibacterial, antifungal, antiviral, antiparasitic) medicines is one of the most important advances in healthcare ever recorded in human history; antimicrobial medicines are an important and valuable resource, but their inappropriate use contributes to the emergence of resistant microorganisms.
The Program operates within the broader context of public health and environmental safety, aiming to mitigate the risks associated with antimicrobial resistance through comprehensive legal and regulatory measures.
The document specifies several key measures and action plans, including the introduction of new tools in outpatient medical records to justify antibacterial therapy, the regulation of systemic antimicrobials for veterinary use, and the analysis of existing legislative frameworks related to environmental emissions. It highlights the importance of developing clinical guidelines, enhancing laboratory capacities, and raising public awareness about AMR.
Compliance requirements include the establishment of oversight mechanisms for prescription practices and the implementation of educational campaigns targeting healthcare professionals and the public.
The implementation plan spans from 2024 to 2027, with specific phases dedicated to ensuring stakeholder involvement and adopting international approaches to AMR prevention. Institutional responsibilities are assigned to various ministries, including Health, Economy, and Environment, which will coordinate efforts to monitor and evaluate the program's progress.
Secondary themes include the need for continuous capacity building among professionals in healthcare, agriculture, and environmental sectors, as well as the involvement of professional medical associations in external monitoring and improvement processes.
Attached files
Date of text
Repealed
No
Source language
English
Legislation Amendment
No